Navigation Links
Leukemia drug found to stimulate immunity against many cancer types
Date:6/11/2014

A class of drug currently being used to treat leukaemia has the unexpected side-effect of boosting immune responses against many different cancers, reports a new study led by scientists at UCL (University College London) and the Babraham Institute, Cambridge.

The drugs, called p110δ inhibitors, have shown such remarkable efficacy against certain leukaemias in recent clinical trials that patients on the placebo were switched to the real drug. Until now, however, they have not been tested in other types of cancer.

The new study, published in Nature, provides the first evidence that such drugs can significantly restrict tumour growth and spread and reduce the chances of relapse for a broad range of cancers. The researchers at UCL, the Babraham Institute and Queen Mary University of London, together with scientists from Genentech, South San Francisco, showed that inhibition of the p110δ enzyme helps to boost the body's immune system to kill tumour cells. The research was funded by Cancer Research UK, the Biotechnology and Biological Sciences Research Council and the Wellcome Trust.

"Our study shows that p110δ inhibitors have the potential to offer effective immunity to many types of cancer by unleashing the body's own immune response," says study co-leader Professor Bart Vanhaesebroeck of the UCL Cancer Institute, who first discovered the p110δ enzyme in 1997. "p110δ is highly expressed and important in white blood cells, called 'leukocytes'. Given that leukaemias are the result of leukocytes becoming cancerous, they are a natural target for p110δ inhibitors. Now, we have shown that blocking p110δ also has the remarkable effect of boosting the body's immune response against leukaemias as well as other cancers."

The team showed that inhibiting p110δ in mice significantly increased cancer survival rates across a broad range of tumour types, both solid and haematological cancers. For example,
'/>"/>

Contact: Harry Dayantis
h.dayantis@ucl.ac.uk
44-020-310-83844
University College London
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. One in 4 children with leukemia not taking maintenance medication, study shows
2. Mechanisms of ibrutinib resistance identified in chronic lymphocytic leukemia
3. Tiny mutation triggers drug resistance for patients with one type of leukemia
4. Major discovery on the mechanism of drug resistance in leukemia and other cancers
5. New drug for non-Hodgkin lymphoma and chronic lymphocytic leukemia passes early test
6. Novel target found for chemotherapy-resistant leukemia cells
7. Moffitt Cancer Centers phase 3 study may be game-changer for acute myeloid leukemia
8. A gene within a gene contributes to the aggressiveness of acute myeloid leukemia
9. Experimental drug shows promise for treatment-resistant leukemias
10. Chemo-free treatment a possibility for leukemia/lymphoma
11. Dartmouth researchers develop new approach to chronic lymphocytic leukemia treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... 23, 2014 Recently, Skmen.com, an experienced ... of 2014 bohemian dresses in its online store. Moreover, ... prices, up to 28% off. All the international clients ... August 31, 2014. , The company’s professional online ... to show worldwide customers more the latest information about ...
(Date:8/22/2014)... Vegas, NV (PRWEB) August 22, 2014 ... email marketing services that currently helps more than ... efforts has caught the attention of Shane Michaels, prompting ... still a crucial element for any online marketing campaign, ... replacing email in the marketing world,” reports Michaels. “AWeber ...
(Date:8/22/2014)... MyWriters.com , an online source ... experts for marketers to help them drive traffic to ... of Shane Michaels, prompting an investigative review. , ... way knows that content is king when it comes ... “But even though content is extremely important, creating quality, ...
(Date:8/22/2014)... This report studies the "Sample Preparation Market ... (Tubes), Kits (Isolation, Purification), By Application (Genomics, Proteomics), ... to 2018" This market was valued at $4,254.8 ... at a CAGR of 5.9% from 2013 to ... Browse 98 market data Tables and 23 Figures ...
(Date:8/22/2014)... 2014 With the stage set for ... Store Expo - which will be held in Boston ... op-ed in its online opinion section, Podium. The ... is co-authored by Steven C. Anderson, IOM, CAE, president ... of the MCPHS University School of Pharmacy – Worcester/Manchester. ...
Breaking Medicine News(10 mins):Health News:Cheap Bohemian Dresses Unveiled by Experienced Supplier Skmen.com 2Health News:AWeber: Review Exposes Affordable Provider of Opt-In Email Marketing Services 2Health News:My Writers: Review Exposes Online Source for Quality Marketing Content 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 2Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 3Health News:Sample Preparation Market by Product and Application Worth $5,672 Million by 2018 - New Research Report by MarketsandMarkets 4Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 2Health News:The Boston Globe Publishes Value of Pharmacy Op-ed as NACDS Total Store Expo Begins 3
... lutenizing hormone-releasing hormone agonist, reduces the long-term risk of ... breast cancer who did not take tamoxifen, according to ... of the Journal of the National Cancer Institute. ... hormone agonists, including goserelin, reduce the risk of disease ...
... to a cardiologist to go through a standard battery of ... coronary artery disease which is the most common cause of ... and these women are sent home with little more than ... similar symptoms and are more likely to develop future cardiac ...
... 24, 2009 Diagnosing acute stroke is a high-pressure ... all the difference. Early treatment can stop brain damage, ... increase the risk of bleeding in the brain. , ... stroke treatmenta clot-busting enzyme known as tissue plasminogen activator ...
... 23, 2009) Postpartum depression is a seriousand often ... mothers. Some of the causes might include personal history ... financial or emotional support. Left untreated, it can have ... on her child,s development. , In the ...
... Hanover Insurance Group, Inc. (NYSE: THG ... to the company,s board of directors at its ... principal of Taggart Associates in Cambridge, Mass., which ... work on corporate and non-profit boards.(Logo: http://www.newscom.com/cgi-bin/prnh/20051031/NEM023LOGO ...
... that can pose a big public health threat, researchers ... their release from Texas prisons, only 5 percent of ... treat their condition within the necessary 10 days, a ... therapy] at this time are at increased risk of ...
Cached Medicine News:Health News:Goserelin improves long-term survival in premenopausal women with early breast cancer 2Health News:Cardiologists initiate STILETTO study to investigate treatment options for women with chest pain 2Health News:Stroke treated significantly faster and just as safely by medical residents 2Health News:Stroke treated significantly faster and just as safely by medical residents 3Health News:Diabetes a risk factor for postpartum depression 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 2Health News:The Hanover Insurance Group Elects Harriett Tee Taggart to Board of Directors 3Health News:Most HIV-Infected Prisoners Go Untreated After Release 2
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
(Date:8/21/2014)... BURLINGTON, Mass. , Aug. 21, 2014 /PRNewswire/ ... of COPD,  physicians in Brazil ... to follow clinical guidelines and commonly prescribe long-acting ... regimens, although they do so within current severe ... combinations (FDCs) that are expected to launch in ...
(Date:8/21/2014)... 2014  Zacks.com announces the list of stocks featured in ... discuss the latest news and events impacting stocks and the ... (NYSE: HPQ - Free Report ), IBM (NYSE: ... SB - Free Report ), GlaxoSmithKline plc (NYSE: GSK ... FI - Free Report ). Today, Zacks is ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 2Novel Fixed-Dose Combinations for COPD in Brazil and Mexico Will Compete With Well-Established Therapies in an Environment Dominated by Aggressive Cost-Control Mechanisms 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 2The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 3The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 4The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 5The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 6The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 7The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 8The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 9The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 10The Zacks Analyst Blog Highlights: Hewlett-Packard, IBM, Safe Bulkers, GlaxoSmithKline and Frank's International 11
... Boston Scientific Corporation (NYSE: BSX ) announces ... be presented at Digestive Disease Week ® (DDW), ... involve the SpyGlass ® Direct Visualization System, WallFlex® ... Needle and Resolution® Clip. "The volume and ...
... Pharmaceuticals, Inc. (NYSE: WPI ) today ... an Abbreviated New Drug Application (ANDA) with the ... to market Norethindrone Acetate/Ethinyl Estradiol and Ethinyl Estradiol and ... 75 mg. Watson,s ANDA product is a generic ...
Cached Medicine Technology:Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 2Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 3Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 4Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ® 5Watson Confirms Lo Loestrin® Fe Patent Challenge 2Watson Confirms Lo Loestrin® Fe Patent Challenge 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: